Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis

Abstract INTRODUCTION Blood‐based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD). METHODS We performed a systematic review and meta‐analysis on the potential of blood phosphorylated Tau181 (p‐tau181) to differentiate amyloid‐positive (A+) and amyloid‐negative (A−) subje...

Full description

Saved in:
Bibliographic Details
Main Authors: Annibale Antonioni, Emanuela Maria Raho, Lamberto Manzoli, Giacomo Koch, Maria Elena Flacco, Francesco Di Lorenzo
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Online Access:https://doi.org/10.1002/dad2.70068
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850064161063567360
author Annibale Antonioni
Emanuela Maria Raho
Lamberto Manzoli
Giacomo Koch
Maria Elena Flacco
Francesco Di Lorenzo
author_facet Annibale Antonioni
Emanuela Maria Raho
Lamberto Manzoli
Giacomo Koch
Maria Elena Flacco
Francesco Di Lorenzo
author_sort Annibale Antonioni
collection DOAJ
description Abstract INTRODUCTION Blood‐based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD). METHODS We performed a systematic review and meta‐analysis on the potential of blood phosphorylated Tau181 (p‐tau181) to differentiate amyloid‐positive (A+) and amyloid‐negative (A−) subjects. Two meta‐analyses were conducted, showing the mean p‐tau values in blood and cerebrospinal fluid (CSF) in the A+ and A− group, and the second comparing the mean p‐tau concentrations in blood and CSF among A+ versus A‐ participants, by laboratory assessment method. RESULTS Eighteen studies (2764 A+ and 5646 A− subjects) were included. The single‐group meta‐analysis showed mean higher blood p‐tau181 values in the A+ than in the A− group. In the head‐to‐head meta‐analysis, blood p‐tau reliably differentiated A+ patients from A− participants. DISCUSSION Regardless of the laboratory technique, blood p‐tau181 reliably differentiates A+ and A− subjects. Therefore, it might have important applications for early diagnosis and inclusion in clinical trials for AD patients. Highlights The role of blood‐based biomarkers in discriminating AD patients is still uncertain. Blood p‐tau181 distinguishes among amyloid‐positive and amyloid‐negative subjects. Blood p‐tau181 might allow early diagnosis and inclusion in clinical trials.
format Article
id doaj-art-373fac85c7414089bb719fb899373307
institution DOAJ
issn 2352-8729
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
spelling doaj-art-373fac85c7414089bb719fb8993733072025-08-20T02:49:22ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292025-01-01171n/an/a10.1002/dad2.70068Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysisAnnibale Antonioni0Emanuela Maria Raho1Lamberto Manzoli2Giacomo Koch3Maria Elena Flacco4Francesco Di Lorenzo5Doctoral Program in Translational Neurosciences and Neurotechnologies Department of Neuroscience and Rehabilitation University of Ferrara Ferrara ItalyDepartment of Neuroscience and Rehabilitation University of Ferrara Ferrara ItalyDepartment of Medical and Surgical Sciences University of Bologna Bologna ItalyNon Invasive Brain Stimulation Unit Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Rome ItalyDepartment of Environmental and Prevention Sciences University of Ferrara Ferrara ItalyNon Invasive Brain Stimulation Unit Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Rome ItalyAbstract INTRODUCTION Blood‐based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD). METHODS We performed a systematic review and meta‐analysis on the potential of blood phosphorylated Tau181 (p‐tau181) to differentiate amyloid‐positive (A+) and amyloid‐negative (A−) subjects. Two meta‐analyses were conducted, showing the mean p‐tau values in blood and cerebrospinal fluid (CSF) in the A+ and A− group, and the second comparing the mean p‐tau concentrations in blood and CSF among A+ versus A‐ participants, by laboratory assessment method. RESULTS Eighteen studies (2764 A+ and 5646 A− subjects) were included. The single‐group meta‐analysis showed mean higher blood p‐tau181 values in the A+ than in the A− group. In the head‐to‐head meta‐analysis, blood p‐tau reliably differentiated A+ patients from A− participants. DISCUSSION Regardless of the laboratory technique, blood p‐tau181 reliably differentiates A+ and A− subjects. Therefore, it might have important applications for early diagnosis and inclusion in clinical trials for AD patients. Highlights The role of blood‐based biomarkers in discriminating AD patients is still uncertain. Blood p‐tau181 distinguishes among amyloid‐positive and amyloid‐negative subjects. Blood p‐tau181 might allow early diagnosis and inclusion in clinical trials.https://doi.org/10.1002/dad2.70068Alzheimer's disease (AD)biomarkersbloodCSFmeta‐analysisphosphorylated Tau181 (p‐tau181)
spellingShingle Annibale Antonioni
Emanuela Maria Raho
Lamberto Manzoli
Giacomo Koch
Maria Elena Flacco
Francesco Di Lorenzo
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Alzheimer's disease (AD)
biomarkers
blood
CSF
meta‐analysis
phosphorylated Tau181 (p‐tau181)
title Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
title_full Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
title_fullStr Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
title_full_unstemmed Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
title_short Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
title_sort blood phosphorylated tau181 reliably differentiates amyloid positive from amyloid negative subjects in the alzheimer s disease continuum a systematic review and meta analysis
topic Alzheimer's disease (AD)
biomarkers
blood
CSF
meta‐analysis
phosphorylated Tau181 (p‐tau181)
url https://doi.org/10.1002/dad2.70068
work_keys_str_mv AT annibaleantonioni bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis
AT emanuelamariaraho bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis
AT lambertomanzoli bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis
AT giacomokoch bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis
AT mariaelenaflacco bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis
AT francescodilorenzo bloodphosphorylatedtau181reliablydifferentiatesamyloidpositivefromamyloidnegativesubjectsinthealzheimersdiseasecontinuumasystematicreviewandmetaanalysis